six The phosphodiesterase-five inhibitor sildenafil is licensed for PAH in FC I–IV in the United states of america and FC II–III in Europe. Endothelin receptor antagonists (ERAs) which include bosentan, sitaxentan and ambrisentan are oral therapies certified for use in PAH. As no oral agent has shown superiority there remains debate concerning